TWI377061B - Fexofenadine suspension formulation - Google Patents

Fexofenadine suspension formulation Download PDF

Info

Publication number
TWI377061B
TWI377061B TW095146788A TW95146788A TWI377061B TW I377061 B TWI377061 B TW I377061B TW 095146788 A TW095146788 A TW 095146788A TW 95146788 A TW95146788 A TW 95146788A TW I377061 B TWI377061 B TW I377061B
Authority
TW
Taiwan
Prior art keywords
weight
volume ratio
suspension
aqueous
aqueous suspension
Prior art date
Application number
TW095146788A
Other languages
English (en)
Chinese (zh)
Other versions
TW200812581A (en
Inventor
Prafulla Agrawala
Kazimierz Chrzan
Rajiv Haribhakti
Matthew Mermey
Curtis J Porcello
Gary Lee Silvey
Vinh Tran
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38120312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI377061(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of TW200812581A publication Critical patent/TW200812581A/zh
Application granted granted Critical
Publication of TWI377061B publication Critical patent/TWI377061B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
TW095146788A 2005-12-14 2006-12-14 Fexofenadine suspension formulation TWI377061B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75030305P 2005-12-14 2005-12-14

Publications (2)

Publication Number Publication Date
TW200812581A TW200812581A (en) 2008-03-16
TWI377061B true TWI377061B (en) 2012-11-21

Family

ID=38120312

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095146788A TWI377061B (en) 2005-12-14 2006-12-14 Fexofenadine suspension formulation

Country Status (38)

Country Link
US (1) US8933097B2 (https=)
EP (1) EP1965768B1 (https=)
JP (1) JP5308824B2 (https=)
KR (1) KR101452792B1 (https=)
CN (1) CN101316580B (https=)
AR (1) AR058323A1 (https=)
AT (1) ATE431137T1 (https=)
AU (1) AU2006326551B2 (https=)
BR (1) BRPI0619895B1 (https=)
CA (1) CA2633086C (https=)
CR (1) CR9993A (https=)
CY (1) CY1109320T1 (https=)
DE (1) DE602006006870D1 (https=)
DK (1) DK1965768T3 (https=)
DO (1) DOP2006000274A (https=)
EC (1) ECSP088532A (https=)
EG (1) EG25866A (https=)
ES (1) ES2327168T3 (https=)
HN (1) HN2008000875A (https=)
HR (1) HRP20090411T1 (https=)
IL (1) IL192067A (https=)
JO (1) JO2549B1 (https=)
MA (1) MA30152B1 (https=)
MY (1) MY146988A (https=)
NO (1) NO339877B1 (https=)
NZ (1) NZ568943A (https=)
PE (1) PE20071003A1 (https=)
PL (1) PL1965768T3 (https=)
PT (1) PT1965768E (https=)
RS (1) RS51135B (https=)
RU (1) RU2405538C2 (https=)
SI (1) SI1965768T1 (https=)
TN (1) TNSN08186A1 (https=)
TW (1) TWI377061B (https=)
UA (1) UA89584C2 (https=)
UY (1) UY30021A1 (https=)
WO (1) WO2007070517A2 (https=)
ZA (1) ZA200803985B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546774B1 (ko) 2008-07-29 2015-08-24 엘지전자 주식회사 휴대 단말기 및 그 동작제어 방법
CA2852447A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
US10130620B2 (en) 2013-07-01 2018-11-20 Aventisub Llc Liquid pharmaceutical composition for oral administration comprising fexofenadine
BR112015032791A2 (pt) * 2013-07-03 2017-07-25 Scherer Technologies Llc R P composição para uso como enchimento de cápsula, e, cápsula
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
CN106806346B (zh) * 2015-12-01 2020-09-11 国药集团广东环球制药有限公司 一种非索非那定盐酸盐干混悬剂制剂及其制备方法
ES3014923T3 (en) 2016-06-16 2025-04-28 Azurity Pharmaceuticals Inc Composition and method for proton pump inhibitor suspension
EP3639812A4 (en) 2017-06-02 2021-03-17 Teika Pharmaceutical Co., Ltd. SOLUBILIZED MICELLA CONSISTING OF A LOW SOLUBLE COMPONENT AND SOLUTION CONTAINING IT
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
EP4199980A1 (en) * 2020-08-18 2023-06-28 Innate S.r.l. Injectable composition and use of said composition
WO2022175829A1 (en) 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
AU2021480621A1 (en) * 2021-12-29 2024-07-18 Opella Healthcare Group Sas Compositions containing fexofenadine
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法
EP4651852A1 (en) 2023-01-20 2025-11-26 Opella Healthcare Group SAS Paraben-free fexofenadine formulations
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
CN1148849A (zh) * 1994-05-18 1997-04-30 赫彻斯特马里恩鲁斯公司 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
WO2003011295A1 (en) 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
CA2514570C (en) * 2003-01-30 2011-09-06 Ethypharm Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
DK2377557T3 (en) * 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
CN101228128A (zh) 2005-07-27 2008-07-23 桑多斯股份公司 一种用于制备取代苯基醚化合物和罗西格列酮的方法
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物

Also Published As

Publication number Publication date
PT1965768E (pt) 2009-08-07
PE20071003A1 (es) 2007-10-03
DK1965768T3 (da) 2009-09-07
WO2007070517A2 (en) 2007-06-21
UY30021A1 (es) 2007-07-31
DOP2006000274A (es) 2007-10-15
JP5308824B2 (ja) 2013-10-09
JP2009519935A (ja) 2009-05-21
HN2008000875A (es) 2012-01-30
UA89584C2 (en) 2010-02-10
TW200812581A (en) 2008-03-16
IL192067A0 (en) 2009-02-11
DE602006006870D1 (de) 2009-06-25
NZ568943A (en) 2010-04-30
KR101452792B1 (ko) 2014-10-22
US20080299211A1 (en) 2008-12-04
CA2633086A1 (en) 2007-06-21
ES2327168T3 (es) 2009-10-26
ATE431137T1 (de) 2009-05-15
MY146988A (en) 2012-10-15
RU2405538C2 (ru) 2010-12-10
BRPI0619895B1 (pt) 2022-04-12
SI1965768T1 (sl) 2009-10-31
WO2007070517A3 (en) 2007-08-23
TNSN08186A1 (en) 2009-10-30
CA2633086C (en) 2011-10-18
CN101316580B (zh) 2011-11-16
ZA200803985B (en) 2009-03-25
CN101316580A (zh) 2008-12-03
RS51135B (sr) 2010-10-31
ECSP088532A (es) 2008-08-29
IL192067A (en) 2010-12-30
CY1109320T1 (el) 2014-07-02
JO2549B1 (en) 2010-09-05
AU2006326551B2 (en) 2012-06-07
CR9993A (es) 2008-09-23
EP1965768A2 (en) 2008-09-10
KR20080074180A (ko) 2008-08-12
US8933097B2 (en) 2015-01-13
RU2008128418A (ru) 2010-01-20
BRPI0619895A2 (pt) 2011-10-25
NO20082904L (no) 2008-09-10
AR058323A1 (es) 2008-01-30
HK1123197A1 (en) 2009-06-12
MA30152B1 (fr) 2009-01-02
HRP20090411T1 (hr) 2010-01-31
PL1965768T3 (pl) 2009-11-30
EG25866A (en) 2012-09-12
AU2006326551A1 (en) 2007-06-21
EP1965768B1 (en) 2009-05-13
NO339877B1 (no) 2017-02-13

Similar Documents

Publication Publication Date Title
TWI377061B (en) Fexofenadine suspension formulation
AU782469B2 (en) Improved pharmaceutical compositions for poorly soluble drugs
KR100338915B1 (ko) 지프라시돈 배합물
CA2567075C (en) Pharmaceutical suspension composition
CA2074215C (en) Improved oral dosing formulations of dideoxy purine nucleosides
EP2648696B1 (en) New form of administration of racecadotril
JP2022525797A (ja) ピリダジノンtrpc5阻害剤の噴霧乾燥された製剤
WO2005013991A1 (ja) ロラタジンを含有するドライシロップ
CN109475546A (zh) 包括依伐卡托和鲁玛卡托及其盐和衍生物的复合制剂的药物联合组合物、其制备方法及含有它们的药物组合物
KR20070036930A (ko) 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
CA2802142C (en) Ciprofloxacin dry syrup composition
Tripathi et al. Physicochemical Characterization and In Vivo Evaluation of Taste-Masked Dextromethorphan Hydrobromide Resinates in Orally Disintegrating Tablets for Antitussive Action
TR2025008650T2 (tr) Etki̇n madde olarak kenodeoksi̇koli̇k asi̇t (cdca) ve di̇ğer i̇lgi̇li̇ yardimci maddeleri̇ i̇çeren farmasöti̇k oral süspansi̇yon bi̇leşi̇mleri̇
HK1123197B (en) Fexofenadine suspension formulation
Shet et al. Formulation and evaluation of taste masked suspension of azithromycin dihydrate
US20090060995A1 (en) Dispersible sustained release pharmaceutical compositions
CA3235733A1 (en) Tadalafil oral suspension
HK1087619B (en) Oral suspension of tegaserod
HK1087619A1 (en) Oral suspension of tegaserod
HK1185800B (en) New form of administration of racecadotril
HK1172252A (en) Pharmaceutical suspension composition

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees